Abstract
Niacin is an effective drug for raising HDL cholesterol and reducing coronary risks, but patients show low compliance with treatment due to severe facial flushing upon taking the drug. A series of bicyclic pyrazole carboxylic acids were synthesized and tested for their ability to activate the niacin receptor. One analog, 23, showed improved potency and lacked flushing at doses that effectively altered the lipid profile of rats.
MeSH terms
-
Animals
-
Cholesterol, HDL / metabolism
-
Dyslipidemias / drug therapy*
-
Fatty Acids, Nonesterified / metabolism
-
Hypolipidemic Agents / chemical synthesis
-
Hypolipidemic Agents / chemistry
-
Hypolipidemic Agents / pharmacology*
-
Mice
-
Niacin / chemistry
-
Niacin / pharmacology*
-
Nicotinic Agonists / chemical synthesis
-
Nicotinic Agonists / chemistry
-
Nicotinic Agonists / pharmacology*
-
Pyrazoles / chemical synthesis
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacology*
-
Rats
-
Receptors, G-Protein-Coupled / agonists
-
Receptors, G-Protein-Coupled / metabolism
Substances
-
Cholesterol, HDL
-
Fatty Acids, Nonesterified
-
Hypolipidemic Agents
-
Nicotinic Agonists
-
Pyrazoles
-
Receptors, G-Protein-Coupled
-
Niacin